Research reportAlterations in cellular IRP-dependent iron regulation by in vitro manganese exposure in undifferentiated PC12 cells

Add time:09/06/2019    Source:sciencedirect.com

Manganese (Mn) may interfere with iron regulation by altering the binding of iron regulatory proteins (IRPs) to their response elements found on the mRNA encoding proteins critical to iron homeostasis. To explore this, the effects of 24-h in vitro manganese exposure (1, 10, 50, and 200 μM Mn) on: (i) total intracellular and labile iron concentrations; (ii) the cellular abundance of transferrin receptor (TfR), H- and L-ferritin, and mitochondrial aconitase proteins; and (iii) IRP binding to a [32P]- labeled mRNA sequence of L-ferritin were evaluated in undifferentiated PC12 cells. In vitro manganese exposure altered the cellular abundance of TfR, H-/L-ferritin, and m-aconitase, resulting in an increase in labile iron. This latter effect led to a decrease in IRP binding activity at the lower (10 and 50 μM) manganese exposures. In contrast, 200 μM manganese exposure increased IRP binding, in spite of the significant increase in labile iron. These data indicate that at lower exposures, manganese directly interfered with IRP-dependent translational events, producing an increase in labile iron, which in turn signaled a decrease in IRP binding at 24 h. At higher exposures, the intracellular burden of manganese resulted in overt cytotoxicity and appeared to compromise the normal compensatory response to increased labile iron, producing increased IRP binding. We conclude that low to moderate manganese exposure interferes with cellular iron regulation, and thus may serve as a contributory mechanism underlying manganese neurotoxicity.

We also recommend Trading Suppliers and Manufacturers of MANGANESE GLYCEROPHOSPHATE (cas 1335-36-0). Pls Click Website Link as below: cas 1335-36-0 suppliers

Prev:Hydrolysis of phosphohydroxypyruvate and β-glycerophosphate by a phosphatase preparation from beef brain☆
Next:8.19 - The Discovery of the MCH-1 Receptor Antagonist NGD-4715 for the Potential Treatment of Obesity)